Home/Pipeline/RB-190

RB-190

Parkinson's Disease

Pre-Phase 2Active

Key Facts

Indication

Parkinson's Disease

Phase

Pre-Phase 2

Status

Active

Company

Right Brain Bio

About Right Brain Bio

Right Brain Bio is a private, pre-revenue biotech challenging the long-standing dopamine deficiency model of Parkinson's disease. The company's core discovery is that excess intracellular dopamine, not a lack of it, drives neurodegeneration, leading to its therapeutic candidate RB-190, a drug that lowers dopamine synthesis. With a seasoned leadership team including former FDA officials and Parkinson's experts, and FDA confirmation that RB-190 is ready for Phase 2 trials, the company is positioned to test its revolutionary hypothesis in patients. Success could fundamentally shift the treatment paradigm for millions of Parkinson's patients worldwide.

View full company profile

Therapeutic Areas

Parkinson's Disease Neurodegenerative Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active